Reference
- Hahn T, Wingard JR, Anderson KC, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based review. Biol Blood Marrow Transplant 2003;9:4–37.
- Ribas C, Colleoni GW. Advances in the treatment of multiple myeloma: The role of thalidomide. L,euk Lymphoma 2003;44:291— 298.
- Anagnostopoulos A, Weber D, Rankin K, et al Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003;121:768–771
- Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–1571.
- Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
- Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003;101:703–705.
- Anderson KC: Moving disease biology from the lab to the clinic. Cancer 2003;97:796–801.
- Hideshima T, Richardson P, Anderson KC. Novel therapeutic approaches for multiple myeloma. Immunol Rev 2003;194:164— 176.
- Orlowski RZ. Bortezomib and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther 2004;4:171— 179.